Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (IVBXF)
:IVBXF
Total Valuation
Innovent Biologics has a market cap or net worth of $11.47B. The enterprise value is $54.07B.
Market Cap$11.47B
Enterprise Value$54.07B
Share Statistics
Innovent Biologics has 1,638,187,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,638,187,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Innovent Biologics’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -8.68%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-8.68%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee1.10M
Profits Per Employee-202.23K
Employee Count5,659
Asset Turnover0.30
Inventory Turnover1.87
Valuation Ratios
The current PE Ratio of Innovent Biologics is -58.77. Innovent Biologics’s PEG ratio is 1.07.
PE Ratio-58.77
PS Ratio―
PB Ratio4.82
Price to Fair Value4.82
Price to FCF-48.89
Price to Operating Cash Flow408.73
PEG Ratio1.07
Income Statement
In the last 12 months, Innovent Biologics had revenue of 6.21B and earned -1.03B in profits. Earnings per share was -0.66.
Revenue6.21B
Gross Profit4.40B
Operating Income-1.68B
Pretax Income-1.14B
Net Income-1.03B
EBITDA-660.68M
Earnings Per Share (EPS)-0.66
Cash Flow
In the last 12 months, operating cash flow was 555.07M and capital expenditures -1.22B, giving a free cash flow of -665.93M billion.
Operating Cash Flow555.07M
Free Cash Flow-665.93M
Free Cash Flow per Share-0.41
Dividends & Yields
Innovent Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.05
52-Week Price Change17.72%
50-Day Moving Average5.33
200-Day Moving Average5.13
Relative Strength Index (RSI)59.19
Average Volume (3m)603.00
Important Dates
Innovent Biologics upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateMar 26, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Innovent Biologics as a current ratio of 3.00, with Debt / Equity ratio of 26.95%
Current Ratio3.00
Quick Ratio2.78
Debt to Market Cap0.06
Net Debt to EBITDA9.73
Interest Coverage Ratio-17.03
Taxes
In the past 12 months, Innovent Biologics has paid -116.50M in taxes.
Income Tax-116.50M
Effective Tax Rate0.10
Enterprise Valuation
Innovent Biologics EV to EBITDA ratio is -81.71, with an EV/FCF ratio of -43.69.
EV to Sales8.70
EV to EBITDA-81.71
EV to Free Cash Flow-43.69
EV to Operating Cash Flow365.21
Balance Sheet
Innovent Biologics has $8.63B in cash and marketable securities with ¥510.00M in debt, giving a net cash position of -$5.28B billion.
Cash & Marketable Securities$8.63B
Total Debt¥510.00M
Net Cash-$5.28B
Net Cash Per Share-$3.22
Tangible Book Value Per Share$8.01
Margins
Gross margin is 71.58%, with operating margin of -27.06%, and net profit margin of -16.56%.
Gross Margin71.58%
Operating Margin-27.06%
Pretax Margin-18.44%
Net Profit Margin-16.56%
EBITDA Margin-10.65%
EBIT Margin-16.85%
Analyst Forecast
The average price target for Innovent Biologics is $6.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.83
Price Target Upside14.21% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―